Form 4: Inhibitor Therapeutics Director Michelle Yanez Reports Acquisition of 50,000 Shares of Common Stock

Michelle Yanez, a director of Inhibitor Therapeutics, Inc., reported acquiring 50,000 shares of common stock on April 1, 2025.

Summary

• On April 1, 2025, Michelle Yanez, a director of Inhibitor Therapeutics, Inc. (INTI), acquired 50,000 shares of common stock.
• The acquisition was reported on a Form 4 filing with the SEC.
• Following the transaction, Yanez directly owns 896,271 shares of Inhibitor Therapeutics, Inc.
• The shares were acquired as compensation under the Issuer's 2014 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither positive nor negative as it simply reports a transaction.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates

Keywords

Form 4, Inhibitor Therapeutics, Michelle Yanez, Stock Acquisition, Director, INTI, Equity Incentive Plan, Common Stock